Flume Mathias, Bardou Marc, Capri Stefano, Sola-Morales Oriol, Cunningham David, Levin Lars-Ake, Touchot Nicolas
Kassenärztliche Vereinigung Westfalen-Lippe, Dortmund, Germany.
CIC INSERM 1432, CHU du Bocage, Dijon, France.
J Mark Access Health Policy. 2016 May 10;4. doi: 10.3402/jmahp.v4.30970. eCollection 2016.
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use. We assessed how the reimbursement and pricing environment allows for IBP in seven European countries, evaluating both incentives and hurdles. In price setting countries such as France and Germany, the Health Technology Assessment and pricing process already accounts for differences of value across indications. In countries where differential value drives coverage decisions such as the United Kingdom and Sweden, IBP is likely to be used, at least partially, but not in the short-term. Italy is already achieving some form of differential value through managed entry agreements, whereas in Spain the electronic prescription system provides the infrastructure necessary for IBP but other hurdles exist.
适应症价值定价法（IBP）在美国已被提议作为一种工具，用于体现药物在不同适应症或患者群体中的差异价值，且目前正处于实施的初期阶段。在欧洲，没有哪个主要国家对适应症价值定价法进行过试验，或者正在认真讨论其使用。我们评估了七个欧洲国家的报销和定价环境如何为适应症价值定价法提供条件，同时评估了激励因素和障碍。在法国和德国等定价国家，卫生技术评估和定价过程已经考虑到不同适应症之间的价值差异。在英国和瑞典等价值差异驱动医保覆盖决策的国家，适应症价值定价法可能至少会部分得到应用，但不会在短期内应用。意大利已经通过有条件准入协议实现了某种形式的差异价值，而在西班牙，电子处方系统为适应症价值定价法提供了必要的基础设施，但也存在其他障碍。
